Shanghai Yizhong: Self-developed innovative drug YXC - 001 clinical trial application accepted.

Shanghai Yizhong announced that its wholly-owned subsidiary, Shanghai Youxi Chuang Medicine Technology Co., Ltd., has officially received approval from the National Medical Products Administration for its clinical trial application for the self-developed innovative drug YXC-001 for the treatment of advanced solid tumors. The product is expected to break through the limitations of treating advanced solid tumors, with preclinical studies showing its effectiveness significantly superior to the control drug. The Drug Review Center will conduct a technical evaluation in the next step, and clinical trials can be conducted after the evaluation is approved. However, the development of innovative drugs carries high risks, and there is uncertainty as to whether they will be approved for clinical use and ultimately go on the market.